Eric T Larson

This inventor holds 7 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignees: University of Washington, Boehringer Ingelheim International Gmbh. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eric T Larson. Retrieved from https://idiyas.com/inventor/eric-t-larson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 15(Granted Patents)

Location History:

Bethel, CT (US) (2017 - 2018)
Seattle, WA (US) (2019 - 2020)
Shoreline, WA (US) (2020 - 2022)

Company Filing History:

6 out of 2,172

University of Washington

patents

1 out of 1,562

Boehringer Ingelheim International Gmbh

patents

Years Active: 2017-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12336821 - Apparatuses, systems, and methods for suppression of artifacts in non-invasive electromagnetic recordings (2025-06-24),

2. 11247972 - Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases (2022-02-15),

3. 10632122 - Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases (2020-04-28),

4. 10544104 - Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases (2020-01-28),

5. 10307425 - Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases (2019-06-04),

6. 9975882 - Heteroaromatic compounds as BTK inhibitors (2018-05-22),

7. 9765037 - Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases (2017-09-19),

Title: Inventor Spotlight: Eric T Larson

Introduction

Eric T Larson is a prominent inventor based in Seattle, WA. With a remarkable portfolio of six patents, he has made significant contributions to the field of medical treatments, specifically in combating parasitic diseases.

Latest Patents

Eric's latest patents focus on innovative compositions and methods for treating toxoplasmosis and cryptosporidiosis, which are caused by infectious eukaryotic parasites. His work emphasizes inhibiting calcium-dependent protein kinases (TgCDPKs and CpCDPKs) using pyrazolopyrimidine and imidazo[1,5-a]pyrazine inhibitors. These patented methods have the potential to greatly enhance therapeutic approaches for diseases linked to apicomplexan protozoan.

Career Highlights

Throughout his career, Eric has worked with notable institutions such as the University of Washington and Boehringer Ingelheim International GmbH. His experience in these prestigious organizations has enriched his research and allowed him to push the boundaries of medical science.

Collaborations

Eric has collaborated with esteemed colleagues, including Wesley C Van Voorhis and Wilhelmus G J Hol. These partnerships have fostered a collaborative environment that drives innovation and enhances the quality of research outcomes.

Conclusion

With his ongoing research and numerous patents, Eric T Larson continues to be a significant figure in the fight against parasitic diseases. His contributions not only advance scientific understanding but also pave the way for new treatment options that could benefit countless individuals around the world.

Profile summary based on public USPTO records.